The Effects of Anlotinib Combined with Chemotherapy following Progression on Cyclin-Dependent Kinase 4/6 Inhibitor in Hormone Receptor-Positive Metastatic Breast Cancer

The Effects of Anlotinib Combined with Chemotherapy following Progression on Cyclin-Dependent Kinase 4/6 Inhibitor in Hormone Receptor-Positive Metastatic Breast Cancer

Purpose. Endocrine therapy combined with cyclin-dependent kinase (CDK) 4/6 inhibitors (CDK4/6i) is the preferred treatment for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2–) metastatic breast cancer (MBC). However, there are currently no recommendations for...

Full description

Saved in:
Bibliographic Details
Main Authors: Ting Xu, Weili Xiong, Lili Zhang, Yuan Yuan
Format: Article
Language:English
Published: Wiley 2024-01-01
Series:The Breast Journal
Online Access:http://dx.doi.org/10.1155/2024/5396107
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items